XLO

Xilio Therapeutics, Inc.

Healthcare · Biotechnology

$295.62 sample

+5.20 (+1.79%) 1D

Market cap

$494.5B

Price as of

2026-10-16

Latest filing

8-K · 2026-10-05

Alerts

8

Price$295.62 -0.08% 3M daily closessample

296.98268.77

2026-07-212026-08-122026-09-032026-09-242026-10-16

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 14INSInsider buy: Chief Financial Officer
Oct 05SEC10-Q filed
Sep 24SEC10-Q filed
Sep 21INSInsider buy: Chief Executive Officer
Sep 14INSInsider buy: Director
Sep 07INSInsider buy: EVP, Operations
Aug 27INSInsider sell: Chief Financial Officer
Aug 19INSInsider buy: General Counsel

Sign up to see the real XLO record →

Company facts

SEC EDGAR registration

Name: Xilio Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -52sample, -100 to +100
Reporting currency: USD

Who is positioning in XLO

sample

Insiders: 10 insider transactions over 90 days, net selling, $623.1M
Congress: 4 members traded over 90 days
Institutions · 13F: 9 funds hold $7.4B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$25.8B +11.2% y/y

Q4 2024Q3 2026

Inventory$15.9B +20.0% y/y

Q4 2024Q3 2026

Accounts receivable$11.2B +8.2% y/y

Q4 2024Q3 2026

Total debt$31.3B +18.3% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $334.3B +9.6% 3M
Sample peer B: $381.4B -5.8% 3M
Sample peer C: $486.4B -0.3% 3M
Sample peer D: $162.9B -4.4% 3M
Sample peer E: $110.1B +6.4% 3M